Apimeds Pharmaceuticals US, Inc. — Form 8-K Summary
Event date: October 4, 2026. The report was signed October 13, 2026. This is an event filing, not a periodic financial report.
Business context
MindWave Innovations Inc., a wholly owned subsidiary of Apimeds Pharmaceuticals US, announced a two-year Master Service Agreement with BlockAssure Inc. MindWave is to build, deploy, operate and maintain AssureChain, a dedicated subnet of MindChain for recording and executing BlockAssure insurance contracts, reinsurance treaties, policies and claims processes on-chain. The agreement renews automatically for successive one-year periods unless either party gives notice of non-renewal.
Financial terms and metrics
- Consideration includes a fixed development fee payable quarterly; the filing does not provide the fee amount.
- Operating and maintenance fees are to be agreed; the filing does not provide a value.
- MindWave is to receive 20% of the total supply of AssureCoin, a digital token BlockAssure plans to create on MindChain. The token’s creation and value are not assured.
- The filing provides no revenue, profit, cash flow, margin, debt, liquidity or other financial performance figures, and no quantified financial impact from the agreement.
Changes, outlook and risks
The agreement is a newly announced business arrangement; the filing provides no prior-period comparison or financial guidance. Its expected execution and benefits depend on development timelines, milestone achievement, acceptance testing, technical performance and integration with third-party systems and data sources. Other stated risks include BlockAssure obtaining and maintaining required licenses, agreement on operating and maintenance fees, market acceptance, and regulatory requirements for insurance, reinsurance and digital assets.
Important facts for investors to verify
- The development fee amount and the operating and maintenance fees ultimately agreed.
- Whether AssureCoin is created, its terms and value, and how the 20% allocation is implemented.
- Project milestones, acceptance testing, deployment status and technical performance.
- BlockAssure’s licensing status and applicable regulatory requirements.
- Any subsequent disclosure of the agreement’s financial contribution or material changes to its terms.